The Power of Three: Helios Bioelectronics, GattaCo, and iAssay Unite to Clobber Infectious Disease
Today, a trio of cutting-edge companies announced a global collaboration that will enable nearly instant medical test results, bypassing traditional biological laboratories and forwarding critical data to doctors, hospitals and appropriate health agencies.
SAN DIEGO, June 23, 2021 (Newswire.com) - From Athos, Porthos and Aramis to Luke, Leia and Han, something magical happens when three unique and powerful forces unite.
Today, a trio of cutting-edge companies announced a global collaboration that will enable nearly instant medical test results, bypassing traditional biological laboratories and forwarding critical data to doctors, hospitals and appropriate health agencies.
"From COVID-19 to leukemia, patients and clinicians need fast and accurate diagnoses," said Lonnie Adelman, CEO and founder of one of the companies, San Diego's iAssay. "This collaboration will revolutionize how scientific and medical data is produced, collected, and shared."
In fact, the techniques pioneered by these three companies - iAssay of San Diego, California; GattaCo of Murrieta, California; and Taiwan's Helios Bioelectronics - can be used by engineers as well as medical professionals. Besides medical and scientific applications, soil or water samples, for instance, could be tested for toxins, minerals or other materials.
Each of the companies brings its unique strengths to this endeavor.
"By using many strands," said Dr. Hardy Chan, CEO of Helios, "we are weaving a stronger rope."
The three weavers:
Helios Bioelectronics is the developer of a multi-patented electrochemical chip, the FET Chip, which identifies targeted elements such as viral proteins or nucleic acids that can be used to identify specific diseases such as COVID-19. Sometimes called "lab on a chip," this nanotechnology enables a vast amount of information to be gathered through assays processed at the point-of-care that would otherwise rely on detection via remote biological laboratories.
Using its patented sample purification technology, GattaCo has developed a plasma separation tool, the A-PON™. The A-PON automatically separates plasma from whole blood collected from a finger-stick without needing a centrifuge. GattaCo is developing a blood analysis cartridge system that integrates its sample purification technology together with Helios Bioelectronics' FET Chip. This cartridge will be read by iAssay's SimpleTest™ base technology with an adaptor specifically developed for the Helios/GattaCo cartridge.
Together the system will enable sensitive, accurate, and precise detection, reducing false positives and negatives.
iAssay's patented SimpleTest™ automatically interprets test and control indications on a variety of tests incubated with samples from patient blood and urine, and potentially other nonmedical analytes. After SimpleTest™ produces a test result, the device transmits the results to the company's SimpleCloud™ hosted by Amazon AWS, where results can compliantly be viewed in a password-protected portal by doctors, hospitals, appropriate state and federal agencies, scientists for research purposes, and for nonmedical applications.
"This partnership has the potential of saving time, yes, but also saving lives," said Dr. Michael McNeely, president of GattaCo. "Knowledge is power, and the sooner patients and their doctors understand what they are dealing with, the sooner they can seek the correct treatment."
"Health and safety are universal needs," said Helios' Chan. "We may be on the other side of the world from our California partners, but we stand shoulder-to-shoulder with them in this essential work."
For further information:
Dr. Hardy Chan
CEO
Helios Bioelectronics
Hardy.chan@heliosbioelectronics.com
Mahmoud Zubaidi
Chief Science Officer
GattaCo
Lonnie Adelman
CEO and Founder
iAssay
Lonnie.adelman@iassay.net
Source: iAssay